Experimental drug shows promise in treating breast, ovarian cancer

A team of Canadian and U.S. researchers has developed a new "sharp-shooter" drug they hope may be a breakthrough in treating several types of aggressive cancer. The drug, known for now as CFI-400945, is a new class of cancer agent that targets an enzyme involved in some malignancies, among them certain types of breast cancer, and ovarian, colorectal, pancreatic and prostate cancers. Read more here.  Read the press release from the Princess Margaret Cancer Centre here.